Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our top-notch dedicated system is used to design specialised libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.


Our library is unique due to several crucial aspects:


  • Receptor.AI compiles all relevant data on the target protein, such as past experimental results, literature findings, known ligands, and structural data, thereby enhancing the likelihood of focusing on the most significant compounds.

  • By utilizing advanced molecular simulations, the platform is adept at locating potential binding sites, rendering the compounds in the focused library well-suited for unearthing allosteric inhibitors and binders for hidden pockets.

  • The platform is supported by more than 50 highly specialized AI models, all of which have been rigorously tested and validated in diverse drug discovery and research programs. Its design emphasizes efficiency, reliability, and accuracy, crucial for producing focused libraries.

  • Receptor.AI extends beyond just creating focused libraries; it offers a complete spectrum of services and solutions during the preclinical drug discovery phase, with a success-dependent pricing strategy that reduces risk and fosters shared success in the project.


PARTNER
Receptor.AI
 
UPACC
Q9H4Q3

UPID:
PRD13_HUMAN

ALTERNATIVE NAMES:
PR domain-containing protein 13

ALTERNATIVE UPACC:
Q9H4Q3; Q5TGC1; Q5TGC2

BACKGROUND:
The PR domain zinc finger protein 13, with its alternative name PR domain-containing protein 13, is crucial for normal brain development. It regulates transcription and is necessary for the differentiation of specific neurons in the hypothalamus, as well as for the normal development of GABAergic cells in the cerebellum.

THERAPEUTIC SIGNIFICANCE:
Understanding the role of PR domain zinc finger protein 13 could open doors to potential therapeutic strategies. Its involvement in serious conditions such as cerebellar dysfunction and pontocerebellar hypoplasia 17 underscores the importance of further research into its functions and mechanisms.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.